Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model.
Sabri SudirmanChing-Shu LaiYi-Ling YanHung-I YehZwe-Ling KongPublished in: Scientific reports (2019)
High blood glucose in diabetic patients often causes cardiovascular diseases (CVDs) that threats to human life. Curcumin (Cur) is known as an antioxidant agent, possesses anti-inflammatory activity, and prevents CVDs. However, the clinical application of curcumin was limited due to its low bioavailability. This study aimed to investigate the ameliorative effects of chitosan-encapsulated curcumin (CEC) on heart and kidney damages in streptozotocin-induced type-1 diabetes C57BL/6 mice model. The results showed that Cur- and CEC-treatments downregulated the blood sugar and total cholesterol level as well as enhanced insulin secretion. However, blood pressure, triglycerides content, and very low-density lipoprotein-cholesterol content were not changed. Histochemistry analysis revealed that both curcumin and chitosan-encapsulated curcumin ameliorated cell hypertrophy and nucleus enlargement in the left ventricular of heart and reduced fibrosis in the kidney, especially after the chitosan-encapsulated curcumin treatment. Our study suggested that chitosan can effectively enhance the protective effect of curcumin on the heart and kidney damages in type-1 diabetes mice model.
Keyphrases
- type diabetes
- drug delivery
- diabetic rats
- heart failure
- cardiovascular disease
- blood pressure
- glycemic control
- left ventricular
- wound healing
- high fat diet
- atrial fibrillation
- hyaluronic acid
- oxidative stress
- single cell
- stem cells
- metabolic syndrome
- heart rate
- left atrial
- high density
- replacement therapy
- anti inflammatory
- weight loss
- aortic valve
- smoking cessation
- cardiovascular risk factors
- hypertensive patients